Karuturi Bala V K, Tallapaka Shailendra B, Yeapuri Pravin, Curran Stephen M, Sanderson Sam D, Vetro Joseph A
Center for Drug Delivery and Nanomedicine and §Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , 986025 Nebraska Medical Center, Omaha, Nebraska 68198-6025, United States.
Mol Pharm. 2017 May 1;14(5):1469-1481. doi: 10.1021/acs.molpharmaceut.6b01088. Epub 2017 Apr 3.
The diameter of biodegradable particles used to coencapsulate immunostimulants and subunit vaccines affects the magnitude of memory CD8 T cells generated by systemic immunization. Possible effects on the magnitude of CD8 T cells generated by mucosal immunization or memory subsets that potentially correlate more strongly with protection against certain pathogens, however, are unknown. In this study, we conjugated our novel host-derived mucosal immunostimulant, EP67, to the protective MCMV CTL epitope, pp89, through a lysosomal protease-labile double arginine linker (pp89-RR-EP67) and encapsulated in PLGA 50:50 micro- or nanoparticles. We then compared total magnitude, effector/central memory (CD127/KRLG1/CD62L), and IFN-γ/TNF-α/IL-2 secreting subsets of pp89-specific CD8 T cells as well as protection of naive female BALB/c mice against primary respiratory infection with MCMV 21 days after respiratory immunization. We found that decreasing the diameter of encapsulating particle from ∼5.4 μm to ∼350 nm (i) increased the magnitude of pp89-specific CD8 T cells in the lungs and spleen; (ii) partially changed CD127/KLRG1 effector memory subsets in the lungs but not the spleen; (iii) changed CD127/KRLG1/CD62L effector/central memory subsets in the spleen; (iv) changed pp89-responsive IFN-γ/TNF-α/IL-2 secreting subsets in the lungs and spleen; (v) did not affect the extent to which encapsulation increased efficacy against primary MCMV respiratory infection over unencapsulated pp89-RR-EP67. Thus, although not observed under our current experimental conditions with MCMV, varying the diameter of nanoscale biodegradable particles may increase the efficacy of mucosal immunization with coencapsulated immunostimulant/subunit vaccines against certain pathogens by selectively increasing memory subset(s) of CD8 T cells that correlate the strongest with protection.
用于共包裹免疫刺激剂和亚单位疫苗的可生物降解颗粒的直径会影响全身免疫产生的记忆性CD8 T细胞的数量。然而,对于黏膜免疫产生的CD8 T细胞数量或可能与针对某些病原体的保护更密切相关的记忆亚群的潜在影响尚不清楚。在本研究中,我们通过溶酶体蛋白酶敏感的双精氨酸接头(pp89-RR-EP67)将我们新型的宿主来源的黏膜免疫刺激剂EP67与保护性巨细胞病毒(MCMV)细胞毒性T淋巴细胞(CTL)表位pp89偶联,并封装在聚乳酸-羟基乙酸共聚物(PLGA)50:50的微米或纳米颗粒中。然后,我们比较了pp89特异性CD8 T细胞的总数、效应/中央记忆(CD127/KLRG1/CD62L)以及分泌IFN-γ/TNF-α/IL-2的亚群,以及在呼吸道免疫21天后,未感染的雌性BALB/c小鼠抵抗MCMV原发性呼吸道感染的保护情况。我们发现,将包裹颗粒的直径从约5.4μm减小到约350nm:(i)增加了肺和脾中pp89特异性CD8 T细胞的数量;(ii)部分改变了肺中但未改变脾中的CD127/KLRG1效应记忆亚群;(iii)改变了脾中的CD127/KLRG1/CD62L效应/中央记忆亚群;(iv)改变了肺和脾中对pp89有反应的分泌IFN-γ/TNF-α/IL-2的亚群;(v)不影响与未封装的pp89-RR-EP67相比,封装对原发性MCMV呼吸道感染疗效的提高程度。因此,尽管在我们目前针对MCMV的实验条件下未观察到,但改变纳米级可生物降解颗粒的直径可能通过选择性增加与保护最密切相关的CD8 T细胞记忆亚群,提高共包裹免疫刺激剂/亚单位疫苗对某些病原体的黏膜免疫效果。